Share on LinkedInShare on LinkedIn

ARTICLE · 07 OCTOBER 2006

The Baxter Healthcare Decision – The Future Of Derivative Crown Immunity

The Full Federal Court’s recent appeal decision in ACCC v Baxter Healthcare Pty Ltd [2006] FCAFC 28 has implications for businesses dealing with government entities and for the general derivative Crown immunity doctrine.

AustraliaAntitrust/Competition Law

The Full Federal Court’s recent appeal decision in ACCC v Baxter Healthcare Pty Ltd [2006] FCAFC 28 has implications for businesses dealing with government entities and for the general derivative Crown immunity doctrine. This update discusses the issues raised as a result of this appeal for businesses dealing with government entities and evaluating whether their conduct may be subject to the Trade Practices Act 1974 (Cth) (Act).

On 24 August 2006, the Full Federal Court affirmed the doctrine of derivative Crown immunity, under which businesses contracting with the Crown benefit from Crown immunity from Part IV of the Act.

The Full Federal Court dismissed the ACCC’s appeal against the initial Federal Court decision of Justice Allsop. It dismissed the appeal as it agreed with the decision of Justice Allsop that, although Baxter Healthcare Pty Ltd (Baxter Healthcare) had engaged in exclusive dealing and misuse of market power, the company was protected from Part IV of the Act by the

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from